Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:IBRX NASDAQ:NUVL NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$75.44-2.1%$64.00$29.31▼$80.20$9.33B0.382.07 million shs2.87 million shsIBRXImmunityBio$8.30+9.4%$8.11$1.83▼$12.43$8.51B0.0231.66 million shs15.25 million shsNUVLNuvalent$103.44+1.9%$101.96$63.56▼$113.01$8.12B1.15561,886 shs145,157 shsOCULOcular Therapeutix$9.76+0.5%$9.04$6.23▼$16.44$2.14B0.935.39 million shs1.71 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%IBRXImmunityBio+6.61%+8.91%+3.84%+28.91%+260.95%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%OCULOcular Therapeutix+2.97%+4.18%+14.37%+13.57%+25.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$75.44-2.1%$64.00$29.31▼$80.20$9.33B0.382.07 million shs2.87 million shsIBRXImmunityBio$8.30+9.4%$8.11$1.83▼$12.43$8.51B0.0231.66 million shs15.25 million shsNUVLNuvalent$103.44+1.9%$101.96$63.56▼$113.01$8.12B1.15561,886 shs145,157 shsOCULOcular Therapeutix$9.76+0.5%$9.04$6.23▼$16.44$2.14B0.935.39 million shs1.71 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%IBRXImmunityBio+6.61%+8.91%+3.84%+28.91%+260.95%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%OCULOcular Therapeutix+2.97%+4.18%+14.37%+13.57%+25.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.82Moderate Buy$96.7530.19% UpsideIBRXImmunityBio 2.86Moderate Buy$14.4077.01% UpsideNUVLNuvalent 2.88Moderate Buy$137.2532.33% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78143.75% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, CYTK, NUVL, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CYTKCytokinetics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$90.00 ➝ $103.005/6/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$119.005/6/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$101.00 ➝ $119.005/6/2026CYTKCytokinetics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$108.005/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M104.87N/AN/A($5.39) per share-13.79IBRXImmunityBio$113.29M73.83N/AN/A($0.51) per share-15.95NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AOCULOcular Therapeutix$51.95M41.11N/AN/A$3.07 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-891.60%N/A-49.62%N/AIBRXImmunityBio-$351.40M-$0.38N/AN/AN/A-310.18%N/A-81.40%5/11/2026 (Estimated)NUVLNuvalent-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%5/7/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.44N/AN/AN/A-511.90%-70.68%-50.53%N/ALatest OCUL, CYTK, NUVL, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026IBRXImmunityBio-$0.08N/AN/AN/A$43.07 millionN/A5/7/2026Q1 2026NUVLNuvalent-$1.35N/AN/AN/A$0.49 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/5/2026Q1 2026OCULOcular Therapeutix-$0.32-$0.40-$0.08-$0.40$12.72 million$10.79 million2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/23/2026Q4 2025IBRXImmunityBio-$0.08-$0.06+$0.02-$0.06N/A$38.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.534.53IBRXImmunityBioN/A5.105.08NUVLNuvalentN/A15.2715.27OCULOcular Therapeutix0.1115.3915.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIBRXImmunityBio8.58%NUVLNuvalent97.26%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%IBRXImmunityBio69.48%NUVLNuvalent10.20%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.24 million121.01 millionOptionableIBRXImmunityBio5901.03 billion313.78 millionOptionableNUVLNuvalent4078.62 million70.60 millionOptionableOCULOcular Therapeutix230218.91 million212.69 millionOptionableOCUL, CYTK, NUVL, and IBRX HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of Canada2 hours ago | marketbeat.comOcular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA planMay 5 at 3:58 PM | msn.comOcular Therapeutix Q1 Earnings Call HighlightsMay 5 at 3:26 PM | marketbeat.comOcular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call TranscriptMay 5 at 3:05 PM | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPSMay 5 at 10:33 AM | marketbeat.comOcular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 10:16 AM | zacks.comOcular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To ExpectMay 5 at 9:20 AM | finance.yahoo.comOcular Therapeutix: Q1 Earnings SnapshotMay 5 at 9:20 AM | chron.comOcular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 EarningsMay 5 at 9:20 AM | finance.yahoo.comOcular Therapeutix™ Reports First Quarter 2026 Financial Results and Business HighlightsMay 5 at 7:00 AM | globenewswire.comOcular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving Average - Here's What HappenedMay 5 at 4:23 AM | marketbeat.comHow Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 TrialMay 1, 2026 | finance.yahoo.comHow The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL)April 30, 2026 | finance.yahoo.comOcular Therapeutix enrolls first patient in SOL-X long-term extension trial for AXPAXLIApril 29, 2026 | ophthalmologytimes.comOOcular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial DataApril 29, 2026 | finance.yahoo.comOcular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMDApril 29, 2026 | globenewswire.comOcular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026April 28, 2026 | globenewswire.comOcular Therapeutix™ to Participate in May Scientific and Investor ConferencesApril 28, 2026 | markets.businessinsider.comOcular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 DataApril 27, 2026 | marketbeat.comOcular Therapeutix (OCUL) Projected to Post Earnings on MondayApril 27, 2026 | marketbeat.comOcular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLCApril 27, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, CYTK, NUVL, and IBRX Company DescriptionsCytokinetics NASDAQ:CYTK$75.44 -1.66 (-2.15%) As of 02:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$8.30 +0.72 (+9.43%) As of 02:59 PM Eastern This is a fair market value price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Nuvalent NASDAQ:NUVL$103.44 +1.97 (+1.94%) As of 02:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$9.76 +0.05 (+0.46%) As of 02:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
